Browse topics

Clinical guides / Orbit

Thyroid eye disease

Updated

At a glance

Autoimmune orbital disease. Assess activity and severity separately; sight-threatening disease needs urgent treatment.

CAVE [1]

  • Reduced colour vision, an afferent pupillary defect, visual loss or corneal breakdown can signal sight-threatening disease.

Clinical presentation [1]

  • Lid retraction, proptosis, irritation, orbital discomfort and restrictive diplopia.

Diagnosis & investigations [1]

  • Measure acuity, colour vision, RAPD, fields when indicated, proptosis, lid aperture/closure, corneal exposure, motility and diplopia. Compare serial measurements with the same method. Orbital imaging is useful for atypical/asymmetric disease, suspected apical compression or surgical planning.
  • At first assessment the 7-item CAS assigns one point each for spontaneous retrobulbar pain, pain on gaze, eyelid redness, conjunctival redness, eyelid swelling, caruncle/plica swelling and chemosis; ≥3/7 supports activity. Severity is assessed separately by functional impact, diplopia, proptosis, exposure and optic nerve compromise.

Differential diagnosis [1]

  • Orbital inflammation, tumour, vascular disease, myasthenia and other causes of restrictive strabismus.

Treatment [1][2]

  • Coordinate endocrinology and ophthalmology, stop smoking and maintain euthyroidism. Choose treatment by activity, severity and patient priorities, not CAS alone. Discuss glucocorticoid-based regimens, other immunomodulation or teprotumumab in an experienced service; local access and safety profile influence selection.
  • Suspected dysthyroid optic neuropathy is an emergency even without marked proptosis. Reduced colour vision, RAPD or new field loss requires same-day escalation. Exposure with epithelial breakdown needs immediate surface protection and possible surgical measures.
Separate activity from severity [1][2]
FindingActionTiming / detail
Mild disease without sight threatLubrication, exposure protection, smoking cessation and stable thyroid function; selected selenium supplementation in selenium-deficient settingsMonitor function and progression; activity alone does not define severity
Active moderate-to-severe disease impairing daily lifeRefer to a combined thyroid-eye service for immunomodulatory treatment; IV glucocorticoid-based therapy remains an established optionEvaluate hepatic, cardiovascular, infectious, glucose and psychiatric risks before systemic treatment
Dysthyroid optic neuropathy or corneal breakdownSame-day specialist emergency management: IV glucocorticoids for DON, with urgent decompression for insufficient response; protect/treat the corneaDo not wait for a high CAS, marked proptosis or routine thyroid appointment
Teprotumumab for adults with moderate-to-severe TEDEU authorised since 19 June 2025; specialist selection with hearing, glucose and inflammatory bowel disease assessment8 IV infusions every 3 weeks; contraindicated in pregnancy. EU authorisation does not ensure local reimbursement
Inactive, stable residual diseasePlan rehabilitation according to need: orbital decompression, then strabismus surgery, then eyelid surgeryConfirm stability; prisms may help selected diplopia while awaiting definitive treatment

Follow-up [1][2]

  • Active or changing disease needs review over weeks, with acuity, colour, cornea and motility repeated; stable mild disease can be spaced further apart. During systemic therapy use the product/regimen-specific laboratory and safety schedule. With teprotumumab, assess hearing before, during and after treatment and monitor glucose; new hearing or bowel symptoms require prompt review.

Risk factors & context [1]

  • Smoking and unstable thyroid function increase concern for deterioration.
  • Assess activity separately from the degree of proptosis.

Complications [1]

  • Compressive optic neuropathy, exposure keratopathy and persistent diplopia.
  • Marked proptosis is not required for sight-threatening optic nerve compression.

When to refer [1]

  • Immediate specialist assessment for suspected dysthyroid optic neuropathy or severe corneal exposure.
References 2
  1. EUGOGO · Clinical practice guidelines for Graves’ orbitopathy ↗2021 · Table 1; activity and severity; sight-threatening disease
  2. EMA · Tepezza (teprotumumab) ↗EU authorisation 19 June 2025 · product information updated 25 March 2026 · Indication; infusion schedule; hearing, glucose, bowel and pregnancy precautions

European guidance. Drug availability and authorisations must be checked locally.

Evidence provenance

Evidence searched through
20 Sept 2026
Geographic applicability
European guidance. Drug availability and authorisations must be checked locally.
Version
fe291a631423
Guideline versions used
  • EUGOGO · Clinical practice guidelines for Graves’ orbitopathy · 2021
  • EMA · Tepezza (teprotumumab) · EU authorisation 19 June 2025 · product information updated 25 March 2026
View references →